{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:46:57Z","timestamp":1784548017702,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00280-020-04163-4","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T15:03:00Z","timestamp":1602342180000},"page":"701-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3276-0130","authenticated-orcid":false,"given":"Yanke","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Plotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"4163_CR1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427\u20131438","journal-title":"Mol Cancer Ther"},{"key":"4163_CR2","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77. https:\/\/doi.org\/10.1186\/bcr2419","journal-title":"Breast Cancer Res"},{"key":"4163_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3","journal-title":"Lancet Oncol"},{"key":"4163_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1185","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1185","journal-title":"Clin Cancer Res"},{"key":"4163_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S (2015) Palbociclib: first global approval. Drugs 75:543\u2013551. https:\/\/doi.org\/10.1007\/s40265-015-0379-9","journal-title":"Drugs"},{"key":"4163_CR6","unstructured":"Loi C, Vaz A, Hoffman J, O'Gorman M, Kirkovsky L, Wang DD, Dalvie D (2014) A phase one open-label single-radiolabeled dose study to investigate the absorption, metabolism, and excretion of [14C]PD-0332991 in healthy male volunteers. ISSX annual meeting"},{"key":"4163_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Lorusso PM, DeMichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18:568\u2013576. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0509","journal-title":"Clin Cancer Res"},{"key":"4163_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/clpt.2009.190","volume":"86","author":"SM Huang","year":"2009","unstructured":"Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ (2009) When to conduct a renal impairment study during drug development: US Food and drug administration perspective. Clin Pharmacol Ther 86:475\u2013479","journal-title":"Clin Pharmacol Ther"},{"key":"4163_CR9","unstructured":"FDA (2010) Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function\u2014Study Design, Data Analysis, and Impact on Dosing and Labeling. FDA Draft Guidance"},{"key":"4163_CR10","doi-asserted-by":"crossref","unstructured":"Sun W, Wang D (2014) A population pharmacokinetic (PK) analysis of palbociclib (PD-0332991) in patients (pts) with advanced solid tumors. Annals of Oncology Supplement 4: iv 146-iv164.","DOI":"10.1093\/annonc\/mdu331.22"},{"key":"4163_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jcph.792","volume":"57","author":"Y Yu","year":"2017","unstructured":"Yu Y, Loi CM, Hoffman J, Wang D (2017) Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol 57:173\u2013184. https:\/\/doi.org\/10.1002\/jcph.792","journal-title":"J Clin Pharmacol"},{"key":"4163_CR12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A (2014) Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos 42:1478\u20131484. https:\/\/doi.org\/10.1124\/dmd.114.058099","journal-title":"Drug Metab Dispos"},{"key":"4163_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1124\/dmd.117.076455","volume":"45","author":"W Huang","year":"2017","unstructured":"Huang W, Nakano M, Sager J, Ragueneau-Majlessi I, Isoherranen N (2017) Physiologically based pharmacokinetic model of the CYP2D6 probe atomoxetine: extrapolation to special populations and drug-drug interactions. Drug Metab Dispos 45:1156\u20131165. https:\/\/doi.org\/10.1124\/dmd.117.076455","journal-title":"Drug Metab Dispos"},{"key":"4163_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cpt.337","volume":"100","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM (2016) Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4\/5. Clin Pharmacol Ther 100:75\u201387. https:\/\/doi.org\/10.1002\/cpt.337","journal-title":"Clin Pharmacol Ther"},{"key":"4163_CR15","first-page":"86","volume":"8","author":"Y Yu","year":"2019","unstructured":"Yu Y, Wang D (2019) Population pharmacokinetic and exposure-response of neutropenia analyses in first-line patients with advanced breast cancer with palbociclib treatment. Clin Pharmacol Drug Dev 8:86\u201387","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4163_CR16","volume-title":"Full Prescribing information","author":"IBRANCE\u00ae capsules (palbociclib).","year":"2019","unstructured":"IBRANCE\u00ae capsules (palbociclib). (2019) Full Prescribing information. Pfizer Inc, New York"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04163-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T22:02:13Z","timestamp":1669154533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04163-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4163"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04163-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are employees of and may hold stock in Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The clinical study protocol, its amendments, and the informed consent forms were reviewed and approved by the Institutional Review Board (IRB) at each of the investigational centers participated in the study. All patients provided written informed consent prior to participation in this study. The study was conducted in compliance with the principles of the Declaration of Helsinki and was conducted in compliance with the International Conference on Harmonization Good Clinical Practice Guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}